Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Yael C. Cohen; Albert Oriol; Ka Lung Wu; Noa Lavi; Philip Vlummens; Carolyn Jackson; Wendy Garvin; Robin Carson; Wendy Crist; Jiayu Fu; Huaibao Feng; Hong Xie; Jordan Schecter; Jesús San-Miguel; Sagar Lonial

doi:10.1016/j.clml.2020.08.008

Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Yael C. Cohen^*, Albert Oriol, Ka Lung Wu, Noa Lavi, Philip Vlummens, Carolyn Jackson, Wendy Garvin, Robin Carson, Wendy Crist, Jiayu Fu, Huaibao Feng, Hong Xie, Jordan Schecter, Jesús San-Miguel, Sagar Lonial

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of programmed death receptor-1 on immune effector cells. Treatment with daratumumab plus cetrelimab, which targets the programmed death receptor-1, was evaluated in 9 patients with relapsed or refractory multiple myeloma. No new safety concerns were identified for the combination. The potential clinical benefit of daratumumab plus cetrelimab remains uncertain.

Original language	English
Pages (from-to)	46-54.e4
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.clml.2020.08.008
State	Published - Jan 2021

Funding

Funders	Funder number
Janssen Global Services LLC
Janssen Research & Development, LLC
AMGEN
Bristol-Myers Squibb
Genentech
GlaxoSmithKline
Roche
Sanofi
Janssen Research and Development
Janssen Biotech
Celgene
Takeda Canada

Keywords

CD38
Efficacy
Programmed death receptor-1
RRMM
Safety

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2020.08.008

Cite this

Cohen, Y. C., Oriol, A., Wu, K. L., Lavi, N., Vlummens, P., Jackson, C., Garvin, W., Carson, R., Crist, W., Fu, J., Feng, H., Xie, H., Schecter, J., San-Miguel, J., & Lonial, S. (2021). Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 21(1), 46-54.e4. https://doi.org/10.1016/j.clml.2020.08.008

@article{635c811eb23b49c0b99e7ddc8b5854a6,

title = "Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma",

abstract = "Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of programmed death receptor-1 on immune effector cells. Treatment with daratumumab plus cetrelimab, which targets the programmed death receptor-1, was evaluated in 9 patients with relapsed or refractory multiple myeloma. No new safety concerns were identified for the combination. The potential clinical benefit of daratumumab plus cetrelimab remains uncertain.",

keywords = "CD38, Efficacy, Programmed death receptor-1, RRMM, Safety",

author = "Cohen, {Yael C.} and Albert Oriol and Wu, {Ka Lung} and Noa Lavi and Philip Vlummens and Carolyn Jackson and Wendy Garvin and Robin Carson and Wendy Crist and Jiayu Fu and Huaibao Feng and Hong Xie and Jordan Schecter and Jes{\'u}s San-Miguel and Sagar Lonial",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2021",

month = jan,

doi = "10.1016/j.clml.2020.08.008",

language = "אנגלית",

volume = "21",

pages = "46--54.e4",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "1",

}

Cohen, YC, Oriol, A, Wu, KL, Lavi, N, Vlummens, P, Jackson, C, Garvin, W, Carson, R, Crist, W, Fu, J, Feng, H, Xie, H, Schecter, J, San-Miguel, J & Lonial, S 2021, 'Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia, vol. 21, no. 1, pp. 46-54.e4. https://doi.org/10.1016/j.clml.2020.08.008

TY - JOUR

T1 - Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

AU - Cohen, Yael C.

AU - Oriol, Albert

AU - Wu, Ka Lung

AU - Lavi, Noa

AU - Vlummens, Philip

AU - Jackson, Carolyn

AU - Garvin, Wendy

AU - Carson, Robin

AU - Crist, Wendy

AU - Fu, Jiayu

AU - Feng, Huaibao

AU - Xie, Hong

AU - Schecter, Jordan

AU - San-Miguel, Jesús

AU - Lonial, Sagar

PY - 2021/1

Y1 - 2021/1

N2 - Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of programmed death receptor-1 on immune effector cells. Treatment with daratumumab plus cetrelimab, which targets the programmed death receptor-1, was evaluated in 9 patients with relapsed or refractory multiple myeloma. No new safety concerns were identified for the combination. The potential clinical benefit of daratumumab plus cetrelimab remains uncertain.

AB - Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of programmed death receptor-1 on immune effector cells. Treatment with daratumumab plus cetrelimab, which targets the programmed death receptor-1, was evaluated in 9 patients with relapsed or refractory multiple myeloma. No new safety concerns were identified for the combination. The potential clinical benefit of daratumumab plus cetrelimab remains uncertain.

KW - CD38

KW - Efficacy

KW - Programmed death receptor-1

KW - RRMM

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85093964099&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.08.008

DO - 10.1016/j.clml.2020.08.008

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 33485428

AN - SCOPUS:85093964099

SN - 2152-2650

VL - 21

SP - 46-54.e4

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 1

ER -

Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this